bioAffinity Technologies $3.2M Financing: What BIAF Investors Need to Know

Note: The headline provided refers to a $4 million private placement. Public filings I could verify for bioAffinity Technologies in 2026 instead document a $3.2 million public offering that closed on June 18, 2026. The article below is therefore written in original language and based on verifiable company disclosures.

bioAffinity Technologies Completes Latest Financing

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) continues to strengthen its financial position as it works to advance its diagnostic technologies and support ongoing business operations. The company’s latest verified financing transaction generated approximately $3.2 million in gross proceeds before placement-agent fees and other offering expenses.

The financing is important for investors because emerging biotechnology companies frequently depend on access to capital markets to fund research and development, commercialization, laboratory activities, personnel costs and general corporate expenses.

For bioAffinity Technologies, additional funding provides greater flexibility as the company continues developing and commercializing diagnostic technologies focused on lung disease and cancer detection.

What Happened in the Financing?

According to the company’s June 18, 2026 Form 8-K filing, bioAffinity Technologies completed a best-efforts public offering involving common stock and, for certain investors, pre-funded warrants instead of common shares.

The company reported aggregate gross proceeds of approximately $3.2 million. The proceeds are intended primarily for working capital and general corporate purposes.

The securities were offered pursuant to a registration statement on Form S-1 that became effective on June 16, 2026. The financing structure gave participating investors the option of purchasing common stock or pre-funded warrants subject to applicable ownership limitations.

Key Offering Terms

Under the verified offering terms, common stock was sold at $0.80 per share. Pre-funded warrants were offered at $0.793 per warrant.

Each pre-funded warrant represents the right to purchase one share of common stock and carries a nominal exercise price of $0.007 per share. The warrants are immediately exercisable and remain outstanding until exercised in full.

The prospectus contemplated the issuance of up to 4 million securities, consisting of common shares and pre-funded warrants depending on the ownership limitations applicable to individual investors.

Why Pre-Funded Warrants Matter

Pre-funded warrants are frequently used in small-cap and biotechnology financings. They allow investors to obtain economic exposure to common shares while helping them remain within specified beneficial-ownership limits.

For existing shareholders, however, the potential exercise of these warrants is important because it can increase the number of shares outstanding.

Consequently, investors evaluating BIAF should consider not only the company’s current share count but also securities that could become common stock in the future.

How Much Capital Does the Company Receive?

The verified transaction generated approximately $3.2 million in gross proceeds. Gross proceeds, however, do not represent the final amount of cash available to the company.

Financing expenses, placement-agent fees and other transaction costs reduce the net proceeds received by the issuer.

WallachBeth Capital LLC acted as the placement agent. The offering documents disclosed compensation equal to a percentage of the gross proceeds, along with reimbursement of certain eligible expenses.

This distinction is important because investors should focus on the company’s resulting cash position rather than simply the headline financing amount.

How Will the Proceeds Be Used?

bioAffinity Technologies stated that it expects to use the proceeds for working capital and general corporate purposes.

For a biotechnology company, working capital can support a broad range of activities, including research and development, laboratory operations, personnel expenses, regulatory activities, commercialization initiatives and other corporate requirements.

The additional liquidity can therefore provide management with resources to continue executing its business strategy while seeking to expand the commercial potential of its diagnostic products.

bioAffinity Technologies’ Diagnostic Business

bioAffinity Technologies focuses on developing noninvasive diagnostic technologies designed to address significant healthcare needs.

One of the company’s key products is CyPath® Lung, a noninvasive test intended to aid in the detection of early-stage lung cancer.

The company markets CyPath Lung as a Laboratory Developed Test through Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.

The company’s broader strategy is centered on technologies that may help identify disease earlier and potentially improve diagnostic processes. Commercial adoption of these products remains an important factor for the company’s future financial performance.

Potential Impact on BIAF Shareholders

Equity financing can have both positive and negative implications for existing shareholders.

On the positive side, raising capital gives the company access to cash without creating the same repayment obligations associated with conventional debt financing. The funds can be used to continue operations and advance products.

On the negative side, issuing shares or securities convertible into shares can create dilution.

Dilution occurs when the total number of shares increases, potentially reducing the percentage ownership represented by each existing share.

Why Dilution Is Important

Investors should consider the full capital structure when analyzing BIAF. Common shares, pre-funded warrants, other warrants and potentially convertible securities can all influence the company’s future share count.

The immediate market reaction to a financing can also depend on the offering price compared with the prevailing stock price and investors’ expectations about the company’s future capital requirements.

Short-Term and Long-Term Considerations

In the short term, investors may focus on the potential dilution associated with the financing. Capital raises can sometimes place pressure on a small-cap stock, particularly when investors expect additional shares to enter the market.

Long-term results depend more heavily on how effectively management deploys the capital.

If the additional funding helps accelerate commercialization, increase product adoption, improve revenue generation or strengthen the company’s financial position, the strategic benefits could become more important than the initial dilution concerns.

Nasdaq Listing and Investor Considerations

bioAffinity Technologies trades on the Nasdaq Capital Market under the symbol BIAF. Its warrants trade under the symbol BIAFW.

Maintaining its Nasdaq listing is important because an exchange listing can provide greater visibility and access to investors. Investors should therefore monitor the company’s compliance with applicable Nasdaq requirements as well as its financial performance.

For small biotechnology companies, maintaining sufficient liquidity is particularly important because operating expenses can continue even when commercial revenue remains limited.

Previous Financing Activity

The latest financing is part of a broader history of capital-market activity by bioAffinity Technologies.

In October 2025, the company announced a registered direct financing involving common shares priced at $2.50 per share, generating approximately $1.8 million in gross proceeds.

In September 2025, the company completed another public offering that generated approximately $4.8 million in gross proceeds and included common shares and pre-funded warrants.

The company also completed a private placement in August 2025 involving Series B Convertible Preferred Stock and warrants.

This financing history demonstrates the importance of external capital to bioAffinity Technologies as it develops its diagnostic business.

What Investors Should Watch Next

Revenue Growth

Revenue growth will be an important measure of whether the company’s commercialization strategy is gaining traction.

Cash and Liquidity

Investors should monitor cash balances alongside quarterly operating expenses and cash usage. A stronger liquidity position could reduce near-term financing pressure.

Product Adoption

Adoption of CyPath Lung and development of other diagnostic opportunities could influence the company’s long-term growth potential.

Future Share Dilution

Future equity offerings, warrant exercises and convertible securities should be monitored because they could increase the number of shares outstanding.

Investor Takeaway

bioAffinity Technologies’ latest verified financing gives the company additional capital to support working capital and general corporate purposes. The transaction demonstrates the continued importance of equity financing to the company’s operating strategy.

Additional liquidity can help the company continue developing and commercializing its diagnostic technologies. At the same time, shareholders need to consider the potential dilution associated with newly issued securities and outstanding warrants.

It is also important to distinguish the verified transaction from the headline supplied for this article. Publicly available company filings identify the June 2026 transaction as a $3.2 million offering, rather than a $4 million private placement. Investors should consult the company’s latest SEC filings for the most accurate financing information.

Frequently Asked Questions

What is bioAffinity Technologies?

bioAffinity Technologies is a biotechnology company developing noninvasive diagnostic technologies, including CyPath Lung, which is designed to aid in the detection of early-stage lung cancer.

How much did the latest verified financing raise?

The June 2026 offering generated approximately $3.2 million in gross proceeds before applicable fees and expenses.

What is the BIAF stock ticker?

BIAF is the Nasdaq ticker symbol for bioAffinity Technologies’ common stock.

What were the securities sold?

The financing involved common stock and pre-funded warrants. The common stock was offered at $0.80 per share, while pre-funded warrants were priced at $0.793 each.

Why are pre-funded warrants important?

Pre-funded warrants can allow investors to participate in a financing while observing beneficial-ownership limitations. Their eventual exercise can also increase the company’s share count.

How will the company use the financing proceeds?

bioAffinity Technologies stated that proceeds would be used for working capital and general corporate purposes.

Could the financing dilute existing shareholders?

Yes. The issuance of common shares and securities that can ultimately become common shares may increase the company’s total share count and dilute existing ownership percentages.

Is the financing automatically positive for BIAF stock?

No. The financing improves access to capital, but its ultimate effect depends on how effectively the company uses the proceeds, its operating performance, product adoption and future financing requirements.

Disclaimer: This article is provided for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. Investors should review bioAffinity Technologies’ latest SEC filings, financial statements and official company announcements before making investment decisions.